Company intelligence / Profile preview
Silo Pharma
Sarasota, Florida, USAsilopharma.com ↗
- Ownership
- Public · SILO
- Development stage
- Preclinical
01
Overview
Silo Pharma develops novel therapeutics for underserved neuropsychiatric and neurological conditions using both traditional drugs and psychedelic compounds. Its lead program, SPC‑15, targets PTSD via an intranasal formulation of a serotonin receptor agonist. SP‑26, a ketamine-loaded implant for chronic pain/fibromyalgia, recently met all endpoints in animal studies. Other assets include an intranasal Alzheimer’s therapy (SPC‑14) and a CNS-homing peptide for multiple sclerosis (SPU‑16). The company leverages academic partnerships to advance its pipeline through streamlined regulatory pathways like FDA’s 505(b)(2).
- Therapeutic areas
- PsychiatryNeurologyRheumatology
- Modalities
- Small molecules (e.g., ketamine)Peptides (e.g., CNS-homing peptides)Psychedelic compounds/formulations
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
University of Maryland Baltimore – licensing agreement for peptides targeting MS/rheumatoid arthritis/SPU–16 developmentColumbia University – option/license agreement on Alzheimer’s/stress disorder assetsZylo Therapeutics Inc. – joint venture on Z-Pod™ transdermal delivery techWuXi AppTec – CRO partner for preclinical studies
04
Financials
- Market cap
- $1.5M
- Total revenue
- $72.1K
- Enterprise value
- $-4M
Beyond the preview
Go deeper on Silo Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silo Pharma.